# Ariel Southeast Angel Partners

> Ariel Southeast Angel Partners is a VC fund backing Health Care. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Savannah, United States
- Total investments: 8
- Last investment: Sep 2021
- Lead investor: 13%
- Last updated: Aug 2026
- Website: http://www.arielsoutheastangels.com

Ariel Southeast Angel Partners is an angel investment group that supports start-up and early stage companies.

## Contacts

5 contacts available for Ariel Southeast Angel Partners. Shizune tracks 7 team members at Ariel Southeast Angel Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ariel-southeast-angel-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 50% |
| Biotechnology | 3 | 38% |
| Therapeutics | 2 | 25% |
| Medical Device | 2 | 25% |
| Medical | 1 | 13% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Seed | 1 | 13% |
| Pre-Seed | 1 | 13% |
| Series B | 1 | 13% |
| Convertible Note | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bill Tausig | Treasurer and Secretary | 0 | — |
| Jim Goodlet | Board of Directors Member / Angel Investor Member / Technology Due Diligence Team Member | 0 | — |
| Joe Isola | Director | 0 | — |
| Nancy Matthews | Director | 0 | — |
| Ray Wenig | President and Chief Operating Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Skintelligent | Developed by Dermatologists & Deep Learning Experts. Developing advanced tech solutions for Health care & Skin care industries | $250K | Pre-Seed | Sep 15, 2021 |  |
| Veriskin | Medical device company dedicated to developing new technologies for skin cancer diagnostics |  | Seed | Oct 26, 2020 |  |
| Zylö Therapeutics | Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $4M | Series A | Sep 26, 2019 |  |
| Zylö Therapeutics | Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $4M | Series A | Sep 26, 2019 |  |
| New View Surgical | New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design andcommercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world. | $2.1M | Series A | Jun 17, 2019 |  |
| RevBio | RevBio is commercializing an injectable, self-setting, osteoconductive bone adhesive biomaterial that can bond bone to bone and bone to metal in a wet field environment. The company's showcase product, Tetranite, is being reviewed by the FDA for a growing body of applications including oral, craniofacial, orthopedic, and neurosurgicalindications. Over time, this synthetic adhesive biodegrades and is replaced by new bone. This unique material will reduce the duration and complexity of medical procedures, allow for more minimally invasive surgeries, and will improve patient outcomes by reducing recovery time and the overall cost of care. | $4M | Convertible Note | Jul 01, 2018 |  |
| New View Surgical | New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design andcommercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world. | $2.5M | Series A | Mar 01, 2017 |  |
| Cognition Therapeutics | Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there arecurrently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates. | $12M | Series B | Sep 08, 2015 |  |

8 of 8 investments shown.

## Co-investors
- [New York Angels](https://shizune.co/investors/profile/new-york-angels) — VC Fund, 4 deals together
- [Boston Harbor Angels](https://shizune.co/investors/profile/boston-harbor-angels) — VC Fund, 3 deals together
- [Chemical Angel Network](https://shizune.co/investors/profile/chemical-angel-network) — VC Fund, 2 deals together
- [Keiretsu Forum](https://shizune.co/investors/profile/keiretsu-forum) — VC Fund, 2 deals together
- [Mid Atlantic Bio Angels](https://shizune.co/investors/profile/mid-atlantic-bio-angels) — VC Fund, 2 deals together
- [SC Launch, Inc.](https://shizune.co/investors/profile/sc-launch) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ariel Southeast Angel Partners invest in?

Ariel Southeast Angel Partners invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ariel Southeast Angel Partners?

Public channels for Ariel Southeast Angel Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ariel Southeast Angel Partners?

The team at Ariel Southeast Angel Partners includes Bill Tausig (Treasurer and Secretary), Jim Goodlet (Board of Directors Member / Angel Investor Member / Technology Due Diligence Team Member) and Joe Isola (Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co